Paid Clinical Trials Mississippi
Discover 176 paid clinical trials in Mississippi. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
AcyclovirPhase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System
Sponsor:
National Center for Research Resources (NCRR)
Location:
Code:
NCT00006132
Conditions
Herpes Simplex
Eligibility Criteria
Sex: All
Age: 0 - 28
Healthy Volunteers: Not accepted
Interventions
acyclovir
REACTA Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Sponsor:
Prokidney
Location:
Code:
NCT05099770
Conditions
Type 2 Diabetes Mellitus
Chronic Kidney Diseases
Eligibility Criteria
Sex: All
Age: 30 - 70+
Healthy Volunteers: Not accepted
Interventions
Renal Autologous Cell Therapy (REACT)
Sham Comparator
Fianlimab & CemiplimabA Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Sponsor:
Regeneron Pharmaceuticals
Location:
Code:
NCT05800015
Conditions
Non-small Cell Lung Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
fianlimab
cemiplimab
Pemetrexed
Paclitaxel
Carboplatin
Observational StudyADVENT Post Approval Study
Sponsor:
Boston Scientific Corporation
Location:
Code:
NCT06431815
Conditions
Paroxysmal Atrial Fibrillation
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
FARAPULSE™ Pulsed Field Ablation System
Adagloxad SimoleninStudy of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
Sponsor:
OBI Pharma, Inc
Location:
Code:
NCT03562637
Conditions
Triple Negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
adagloxad simolenin combined with OBI-821
Globo H IHC Assay
Standard of care treatment
OBT076Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Sponsor:
Oxford BioTherapeutics Ltd
Location:
Code:
NCT04064359
Conditions
Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
OBT076, a CD205-directed antibody-drug conjugate
OCTAPLEXStudy of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
Sponsor:
Octapharma
Location:
Code:
NCT04867837
Conditions
Acute Major Bleeding
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Octaplex
SonrotoclaxA Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
Sponsor:
BeiGene
Location:
Code:
NCT05952037
Conditions
Waldenstrom Macroglobulinemia
Waldenstrom's Macroglobulinemia Recurrent
Waldenstrom's Macroglobulinemia Refractory
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Sonrotoclax
Zanubrutinib
AXA1125Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Sponsor:
Axcella Health, Inc
Location:
Code:
NCT04880187
Conditions
Non Alcoholic Steatohepatitis (NASH)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
AXA1125
Placebo
AZD2373Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06824987
Conditions
APOL1-Mediated Kidney Disease
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
AZD2373-Arm 1
AZD2373-Arm 2
Placebo
APOL1 Genotyping Clinical Trial Assay